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Abstract
The clinical and epidemiological profiles of differentiated thyroid cancers (DTCs) have changed in the last three 
decades. Today’s DTCs are more likely to be small, localized, asymptomatic papillary forms. Current practice is, 
though, moving toward more conservative approaches (e.g. lobectomy instead of total thyroidectomy, selective 
use of radioiodine). This evolution has been paralleled and partly driven by rapid technological advances in the 
field of diagnostic imaging. The challenge of contemporary DTCs follow-up is to tailor a risk-of-recurrence-based 
management, taking into account the dynamic nature of these risks, which evolve over time, spontaneously and in 
response to treatments. This review provides a closer look at the evolving evidence-based views on the use and utility 
of imaging technology in the post-treatment staging and the short- and long-term surveillance of patients with DTCs. 
The studies considered range from cervical US with Doppler flow analysis to an expanding palette of increasingly 
sophisticated second-line studies (cross-sectional, functional, combined-modality approaches), which can be used to 
detect disease that has spread beyond the neck and, in some cases, shed light on its probable outcome.
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Introduction
The clinical and epidemiological profiles of differentiated 
thyroid cancers (DTCs) have evolved remarkably over the 
past 30 years. In the 1980s and 1990s, patients usually 
presented with palpable primaries, often accompanied 
by locoregional or even distant metastases (1, 2). Today’s 
DTCs are more likely to be small, localized, asymptomatic 
papillary forms, many with subcentimeter diameters (3). 
These changes have been paralleled and in large part 
driven by advances in diagnostic imaging technology. 
Since the late 1980s, clinicians’ toolboxes for examining 
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the interior of the human body have expanded rapidly 
to include gray-scale ultrasonography (US), Doppler flow 
analysis, computed tomography (CT), magnetic resonance 
imaging (MRI), and positron emission tomography (PET). 
Widespread clinical use of these new techniques for 
assessing structures in the head and neck (e.g. carotid 
arteries) has been responsible for the incidental discovery 
of many of the tiny, silent thyroid cancers being diagnosed 
and treated today (4, 5, 6).
The evolving profile of DTCs has been mirrored by 
changes in our approaches to their treatment and fol-
low-up. The standard of care before the 2000s involved 
total thyroidectomy (often with neck dissection), liberal 
use of radioiodine remnant ablation (RRA), and life-long 
surveillance based chiefly on whole-body radioiodine 
scintigraphy (WBS) and serum thyroglobulin (Tg) assays. 
Support is now growing for more conservative strategies 
in selected cases: lobectomy, omission of RRA, even active 
surveillance alone, which is now an option for some pap-
illary microcarcinomas (7, 8, 9). These changes, too, have 
been facilitated by the availability of new imaging tools 
and techniques. The frequent use in the past of aggressive 
treatments (e.g. total thyroidectomy followed by RRA) 
was dictated in part by the need to eradicate not only the 
neoplastic thyroid tissue but normal thyroid remnants as 
well, since their uptake of iodine and production of thyro-
globulin diminished the diagnostic performance of WBS 
and Tg assays during postoperative surveillance. These 
constraints were attenuated by increasing reliance on US 
surveillance, freeing clinicians to consider more individu-
alized treatments for DTCs.
Despite the relatively indolent nature of most thyroid 
cancers and the increasing prevalence of low-risk tumors, 
the early 2000s witnessed striking increases in the use of 
imaging technology for assessing DTCs. A recent analysis 
of over 23 000 cases of DTC diagnosed in the U.S. con-
firmed that, although the tumors identified between 2001 
and 2009 were more likely to be small (<1 cm) and local-
ized than in previous years, patients were more rather 
than less likely to undergo I-131 scintigraphy and cervi-
cal US (odds ratios, 1.44 (95% confidence interval (CI), 
1.35–1.54) and 2.15 (95% CI: 2.02–2.28) respectively) 
(10). PET studies increased more than 30-fold between 
1996–2004 and 2005–2009, even in patients with local-
ized disease (11).
Efforts are needed to curb this ‘diagnostic hyperactivity’ 
and bring post-treatment management strategies more 
in line with the current challenges of thyroid cancer (9, 
12). Aside from the increasing demands for cost-efficient 
healthcare policies, there is a growing  awareness that the 
increased use of diagnostic imaging does not inevitably 
translate into increased overall survival. Greater 
consideration is being given to the potential risks of 
imaging-related radiation exposure (11) and the impact 
of excessive surveillance on patients’ quality of life (13).
Signs of change are already in the air. Although the 
major goal of post-treatment surveillance of patients with 
DTC is still the timely detection and effective management 
of persistent or recurrent cancer, increasing emphasis is 
being placed on the need to reliably identify patients who 
are disease-free and therefore eligible for less-intensive 
surveillance. Recommendations by national and interna-
tional bodies are increasingly based on assessments of the 
individual patient’s risk of recurrence (rather than death) 
(Table 1). Emphasis is also being placed on the dynamic 
nature of these risks, which evolve over time, spontane-
ously and in response to treatment (14).
This review will provide a closer look at the evolving 
evidence-based views on the use and utility of imaging 
technologies in the post-treatment staging and the 
short- and long-term surveillance of patients with DTCs. 
The modalities considered range from whole-body 
radioiodine scintigraphy and cervical US with Doppler 
flow analysis – the ‘work horses’ in both settings – to an 
expanding palette of increasingly sophisticated cross-
sectional, functional, combined-modality imaging 
approaches, which can be used to detect disease that has 
spread beyond the neck and, in some cases, shed light on 
its probable  outcome.
Cervical ultrasonography
Cervical US includes gray-scale studies performed with 
high-resolution linear transducers (frequencies of 10 to 
15–17 MHz) (15) and assessment of lesion vascularity 
with color or power Doppler. First used in the late 
1980s to distinguish cystic from solid thyroid nodules 
Table 1 American Thyroid Association criteria for assessing 
risk of recurrence in patients with DTC.
Risk Features
Low Intrathyroid tumor
≤5 lymph node micrometastases (<0.2 cm)
Intermediate Aggressive histology, minor extrathyroid 
extension, vascular invasion
>5 involved lymph nodes (0.2–3 cm)
High Gross extrathyroid extension, incomplete 
tumor resection
Lymph node metastases >3 cm
Distant metastases
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
www.eje-online.org
175:5 R187Review L Lamartina and others Imaging in the follow-up 
of DTCs
(15), ultrasound’s popularity increased steadily. By the 
early 2000s, a growing body of evidence indicated that 
sonographic examination of the neck combined with 
serum thyroglobulin assays was the most sensitive 
approach for detecting locoregional DTC involvement 
(16, 17, 18, 19). In 2006, it was officially recommended 
for this purpose by the American Thyroid Association 
(ATA) (20), replacing WBS, which had been the procedure 
of choice for over 40 years.
Cervical US is inferior to WBS in terms of specificity, 
and it provides no information on extracervical 
recurrence, including the upper mediastinum. It is 
also unsuitable for exploring deep cervical structures 
(e.g. retro- or parapharyngeal areas) (12). However, high-
resolution US can pinpoint lesions as small as 2–3 mm in 
the thyroid bed or cervical lymph nodes, where the vast 
amount of persistent/recurrent disease is found in DTC 
patients. In addition, its diagnostic yield is unaffected 
by the radioiodine-avidity of the lesions or the presence 
of anti-Tg antibodies, which can cause false-negative 
findings in WBS and serum Tg assays (19), and it offers a 
number of practical advantages, including low cost, wide 
availability, and no known adverse effects (21).
Its main shortcoming is operator dependency, a prob-
lem aggravated by the diverse profiles of the operators 
examining thyroid cancer patients (e.g. radiology tech-
nicians, radiologists, endocrinologists, and other clinical 
specialists caring for these patients). Efforts have thus been 
made to define minimum criteria for operators claiming 
expertise in cervical US and to standardize methods for 
conducting, interpreting, and documenting the exami-
nation results (12). A second important limitation of US 
is its relatively low specificity, which will be discussed at 
greater length below.
Normal, suspicious, and indeterminate 
findings
Numerous US findings have been analyzed over the years 
as markers of persistent and recurrent foci of thyroid 
cancer in the neck. Those considered most useful for this 
purpose by the European Thyroid Association (ETA) are 
shown in Figs 1 and 2. Their sensitivities and specificities 
vary widely, and ‘suspicious’ lesions are thus distinguished 
from ‘indeterminate’ findings, which are atypical but also 
relatively common in the absence of malignancy.
The low specificity of US findings for distinguishing 
benign and malignant lesions increases when they are 
confirmed by cytological analysis of US-guided FNA 
and/or assay of the needle washout fluid for Tg (22, 23, 
24); the washout fluid can also be subjected to PCR-
based assay of thyroid-specific gene (Tg, TSH receptor) 
transcripts (25). Current trends, however, are characterized 
by more cautious use of biopsy (9). Decisions are based 
on lesion size and/or growth and the likelihood that 
management will change if positive results emerge. These 
recommendations reflect a growing awareness of the 
stress, morbidity, and costs associated with biopsy (26). 
More importantly, in at least 30% of cases, reoperation for 
pathologically confirmed metastases fails to eradicate the 
disease. It also carries an increased risk of serious, often 
permanent complications, including nerve resection, 
hypoparathyroidism, and tracheal or esophageal damage 
(27, 28). Finally, analysis of surgical pathology data on 
prophylactic neck dissections indicate that up to 90% of 
patients with papillary microcarcinomas (<1 cm) have 
level VI lymph node metastases, and up to 40% have 
lateral compartment involvement (29, 30, 31). These 
figures far exceed the clinical locoregional recurrence rates 
reported for these patients, suggesting that a substantial 
portion of the cervical disease detected during follow-up 
is clinically insignificant. FNA should thus be undertaken 
only after careful consideration of costs, benefits, and the 
patient’s own preferences.
Thyroid bed
Thyroid bed lesions are a particular concern owing to 
the proximity of vital structures that can be compressed/
damaged by residual tumor growth (but also by repeat 
encounters with the surgeon’s scalpel, owing to the 
presence of scar tissue). Postoperative exploration of this 
area should be postponed until at least 3 months after 
surgery (12, 32). Even then, distinguishing benign and 
malignant lesions in this area on the basis of US alone is 
undeniably difficult (Fig. 1). Hypoechogenicity alone may 
represent autoimmune thyroiditis, suture granulomas, 
benign reactive lymph nodes, parathyroid adenomas (12), 
and jugular chain LNs that have slid medially to occupy 
the bed (33).
Discordant findings have emerged from the few 
small studies that assessed the diagnostic value of US 
abnormalities against pathology findings. Lee et  al. (34) 
concluded that benign and malignant lesions could 
indeed be distinguished on the basis of their margin 
characteristics, shapes, and calcification statuses. 
Margin irregularity (Fig. 2E) – a feature whose detection 
is associated with particularly high interoperator 
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Figure 1
Classification of post-treatment sonographic findings in the thyroid bed. Panels A and B. Normal findings: (A) The thyroid bed 
after total thyroidectomy: the hyperechoic bilateral paratracheal areas are consistent with the postoperative proliferation of 
fibrofatty connective tissue (arrows); (B) normal left tracheal thyroid gland remnant (arrows): ovoid area, hyperechoic vs anterior 
muscle tissue. Panels C and D. Indeterminate findings: left tracheal thyroid bed nodule (arrows): small, ovoid, hypoecoic nodule, 
without signs of vascularization, and other US suspicious features. Panels E, F and G. Suspicious findings: (E) A hypoechoic nodule 
in the left tracheal thyroid bed (arrows) appears taller-than-wide with irregular margins; (F) suspicious left tracheal thyroid bed 
nodule (arrows) with hypoechoic areas and punctate hyperechogenicity representing microcalcifications; (G) left tracheal thyroid 
bed nodule (arrow): longitudinal scan of a cystic area, with posterior acoustic enhancement. E, esophagus; LC, left carotid artery; 
RC, right carotid artery; T, trachea; US, ultrasound.
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Figure 2
Classification of post-treatment sonographic findings of cervical lymph nodes. Panels A and B. Normal findings: This right cervical 
lymph node (arrows) has a hyperechoic hilum, an elongated shape, short axis ≤5 mm, and exclusively hilar vascularization. Panel 
C. Indeterminate findings: Right cervical lymph node (arrows) with loss of hilum, round shape, and short axis ≥5 mm. Panels D, E 
and F. Suspicious findings: (D) Right cervical lymph node (arrows): thyroid-tissue-like appearance and microcalcifications with 
posterior shadowing; (E) suspicious left cervical lymph node (arrows) with cystic areas with posterior acoustic enhancement; (F) 
round right cervical lymph node (arrows) displaying peripheral vascularization. LC, left carotid artery; LJ, left jugular vein;  
RC, right carotid artery; RJ, right jugular vein; US, ultrasound.
www.eje-online.org
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variability (35) – emerged as the most sensitive (79%) 
and specific (100%) predictor of thyroid bed recurrence. 
This feature, however, was found in only 10% of the 
confirmed recurrences reported by Shin et al. and 6% of 
those classified as ‘non-recurrences’. In fact, they found 
no significant differences between these two classes of 
lesions in terms of size, shape, echogenicity, margins, 
calcification, or vascularity and concluded that they could 
not be reliably differentiated without biopsy (36).
The ETA currently recommends FNA for sonographi-
cally suspicious thyroid bed lesions that measure 10 mm 
or more or display active growth (12). For smaller nodules 
(<11 mm), growth is actually rare (<10% of cases), particu-
larly when they exhibit no suspicious features (Figs 1 and 
2) and are not accompanied by cervical lymphadenopa-
thy or detectable/increasing Tg production. The growth 
that does occur is typically quite slow (roughly 1 mm/
year), suggesting that small thyroid bed nodules can be 
safely managed with cautious observation and serial sono-
graphic examinations of the neck (37).
Cervical lymph nodes
Metastatic involvement is more commonly found in level 
III, IV, and VI nodes than in those of level II (38,  39). 
Normal nodes are typically oval, with short to long 
axis ratios of <0.5 (Fig.  2A) (15). Size provides limited 
information on the likelihood of malignancy. Normal 
ranges vary with the location, with larger nodes found 
in the submandibular region (level II), possibly because 
of reactive phenomena related to chronic oral cavity 
inflammation. Furthermore, many metastatic nodes are 
normal in size (40).
Studies correlating preoperative sonographic and sur-
gical histology findings indicate that a nonvisualized hilus 
is the most sensitive predictor of lymph node malignancy 
(100%), but its specificity was dismally low (29%). The 
most specific findings are cystic changes (100%), punc-
tuate hyperechogenicity (representing colloid or micro-
calcifications) (100%), and peripheral vascularization 
(82%), which also display relatively high sensitivity (86%) 
(38). In light of these findings, a productive  strategy for 
 pinpointing worrisome lymph nodes might begin with a 
thorough Doppler-based assessment of vascularity in all 
nodes lacking a hilus (15).
The ATA reserves FNA for sonographically suspicious 
lymph nodes that exceed 8–10 mm (smallest diameter) 
and/or display active growth (9). Nodes with suspicious 
and especially indeterminate findings do not generally 
increase in size. In a retrospective study on the natu-
ral course of US-detected lymph node abnormalities in 
166  patients followed with serial US, only 20% of the 
abnormal nodes lesions grew ≥3 mm during the first 
3 years after surgery; moreover, none caused pain or com-
pression of vital structures, and 14% disappeared entirely 
over time, with no treatment at all (41).
Post-treatment staging and surveillance
Ultrasound plays an especially important role in the 
early surveillance of the growing subpopulation of DTC 
patients treated with lobectomy or with total/near total 
thyroidectomy without RRA (12, 42, 43). In the presence of 
normal thyroid tissue (even small remnants), the result of a 
single serum Tg assay is of limited use. In these cases, Tg assays 
provide reliable information on the presence of persistent/
recurrent disease only later, when serial measurements are 
available, and can be analyzed to identify increases in Tg 
production over time (44, 45, 46, 47). Substantial rises are 
an indication for additional imaging work-up (US and/or 
second-line studies) (Fig. 3) (9, 12).
Normal findings in the initial post-treatment neck 
scan are strongly associated with excellent long-term 
outcomes (14). The negative predictive power is virtu-
ally 100% in very low-risk patients with microPTCs (48) 
and excellent in intermediate-risk patients as well. Peiling 
Yang et al. reviewed 90 cases of ATA intermediate-risk PTC 
treated with total thyroidectomy and RRA, with negative 
basal Tg and TgAb assays, and negative or only indetermi-
nate findings (Figs 1 and 2) on the first post-treatment US. 
Figure 3
Risk-stratified use of diagnostic imaging modalities in the initial post-therapeutic staging of differentiated thyroid cancer. (a) Risk 
of persistent/recurrent disease as reported in the 2015 American Thyroid Association Guidelines for the Management of Thyroid 
Nodules and Differentiated Thyroid Cancer (Haugen 2015). (b) In patients with uptake on DxWBS, SPECT–CT allows (i) more 
precise anatomical localization of radioiodine uptake, (ii) exclusion of nonspecific uptake, and (iii) identification of noniodine-
avid lesions. (c) 18FDG/PET helps identify patients at highest risk for rapid disease progression and disease-specific mortality 
(prognostic role) and/or those with radioiodine-refractory disease (predictive role). 18FDG/PET, 18F-fluorodeoxyglucose positron 
emission tomography; CT, computed tomography; DxWBS, diagnostic whole-body scan; MRI, magnetic resonance imaging; SPECT, 
single-photon emission computed tomography; Tg, thyroglobulin; US, ultrasound.
www.eje-online.org
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The rate of structural disease recurrence during follow-up 
(median 10 years) was 8% (4/49) in the subgroup whose 
initial US findings were negative (as opposed to 12% 
(5/41) in the group with indeterminate scan results) (49).
In many facilities, neck sonography is still done rou-
tinely, once or even twice a year, even when the risk of 
recurrence is low (12, 50). A recent retrospective analy-
sis of over 1000 cases of PTC treated between 2000 and 
2010 at Memorial Sloan Kettering Cancer Center found 
that during the first 3 years of surveillance, the num-
ber of US examinations per patient ranged from 1.3 in 
low-risk patients to 1.9 and 1.8 in intermediate- and 
high-risk groups – already appreciably lower than rates 
reported in other retrospective studies (51). Nonethe-
less, the number of scans needed to detect 1 recurrence 
event in the low-risk cohort (154.0) was 6–7 times higher 
than those of the intermediate and high-risk groups (23.9 
and 13.0  respectively), indicating that there is substantial 
room for improving the cost-effectiveness of US surveil-
lance of low-risk patients (50).
Similar conclusions were reached in the study cited 
above by Peiling Yang et al. (49). The 90 intermediate-risk 
patients they retrospectively reviewed were followed with 
routine cervical US and Tg assays at 6–12 month intervals, 
and structural recurrence emerged in only 9 (10%). All 
the lesions were sonographically detected. However, in 
5/9 cases, the disease was also heralded by other findings 
(rising Tg levels in most cases) and would thus have been 
identified even if US had not been used so frequently. 
These authors also underscored the high probability of 
false-positive findings associated with frequent US exam-
inations in populations of this sort. In 51 (57%) of the 
cohort patients, the routine scans yielded new or persis-
tently atypical findings, which led to a host of additional 
diagnostic procedures (first- and second-line imaging 
procedures, FNA), none of which disclosed any clinically 
significant structural disease. On the basis of these find-
ings, these authors suggest that in intermediate-risk DTC 
patients whose initial post-treatment assessment reveals 
no structural or biochemical evidence of disease, sono-
graphic surveillance can be discontinued if the second 
assessment is also negative (49).
These conclusions are supported by recent findings 
confirming the strong associated between normal find-
ings at the initial assessment and excellent long-term out-
comes (14). They are also consistent with the ETA’s current 
guidelines regarding the first 5 years of follow-up, when 
over three-quarters of recurrences are identified (3). Dur-
ing this period, yearly US scans are recommended only 
for patients meeting the ETA’s high-risk criteria (some 
of whom are classified as intermediate-risk  according to 
ATA criteria) and only when warranted by pTNM  staging, 
serum Tg levels, and responses to therapy (12). For low- 
and very low-risk patients with normal findings at 6 
months, ‘regular’ scans are considered unnecessary. 
When doubts on the presence of distant metastases 
arise, additional imaging is required (Fig. 3). The follow-
ing section provides a concise profile of the methods most 
commonly used.
Cross-sectional imaging
The cross-sectional imaging studies include CT and MRI 
scans. Both allow high-precision anatomic localization 
and measurement of disease foci and are especially 
useful for assessing the tumor burden in patients with 
extensive local disease or distant metastases. To identify 
the nature of the mass, however, the results have to be 
interpreted within the clinical context of the individual 
patient. When doubts arise or discordant findings emerge 
(e.g. a lesion compatible with metastatic lung disease 
in a low-risk patient with undetectable serum Tg and 
negative Tg antibody assays), cytological or histological 
confirmation is needed. When foci of metastatic disease 
are found, options include local or systemic therapy 
and simple surveillance alone. Lesions that represent no 
immediate threat to the patient should be treated only if 
the tumor burden is substantial or when there is obvious 
progression. The latter can be documented using the 
Response Evaluation Criteria in Solid Tumors, RECIST 
1.1 system) (52).
Evidence supporting the utility of cross-sectional 
imaging modalities comes largely from experience with 
other solid tumors; data on their specific use in thyroid 
cancer are lacking. According to the ATA, cross-sectional 
imaging of the neck and chest should be considered in 
the following cases: (i) patients with extensive recurrent 
nodal disease; (ii) patients with negative findings on cer-
vical US and WBS and a high serum Tg level (generally 
exceeding 10 ng/mL), or rising Tg or Tg antibodies values; 
and (iii) in cases where reliable assessment of potential 
aerodigestive tract invasion is needed (9). Rarer sites of 
thyroid cancer metastases should be explored when a 
clinical suspicion arises or in high-risk patients with high 
serum thyroglobulin levels (10 ng/mL) and no evidence of 
lung/mediastinal metastases (Fig. 3).
The optimal timing for cross-sectional imaging stud-
ies in patients with DTC is not well defined: recom-
mendations range from 3 to 12 months after treatment, 
depending on the tumor burden, location of the disease, 
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histology, and Tg trend (9). Anyway, many thyroid can-
cer clinical trials have enrolled patients with progressive 
 disease evaluated over a period of ≤12 months and base-
line assessment performed no more than 4 weeks before 
treatment introduction (52).
Computed tomography
The anatomic resolution of a CT scan is sufficiently high to 
allow precise localization of disease foci, and compared with 
other second-line studies, it offers distinct advantages in 
terms of availability, cost, and examination times. The lungs 
can be explored with high-resolution CT without contrast 
(9), but contrast-enhancement with iodine is best for 
exploration of the mediastinum. Contrast-enhanced scans 
are also recommended before surgery to identify possible 
areas of vascular invasion; for assessment of the retro-
tracheal space, it is used as a complement to neck US (9).
The radiation exposure associated with CT imaging 
has been linked to an increased risk of cancer (53). This 
risk should be weighed against the aggressiveness of the 
patient’s disease when decisions are being made on the 
use and frequency of CT in the post-treatment surveil-
lance of DTC patients.
Magnetic resonance imaging
Unlike CT, MRI is associated with absolutely no radiation 
exposure. It offers excellent soft-tissue contrast, which 
is particularly useful when esophageal and/or tracheal 
invasion is suspected (54, 55). Although its specificity 
is relatively low (51%), MRI offers excellent sensitivity 
(95%) for the detection of metastatic lymphadenopathy 
in DTC patients (56). It is particularly useful for ruling 
out nodal involvement in the mediastinum (57), which 
is poorly visualized on ultrasound. Its main shortcomings 
are related to the duration of the examination and the 
possibility of false-negative findings related to movement 
artifacts.
MRI is the imaging modality of choice for identify-
ing thyroid cancer metastases to the bone, brain, or liver. 
The bones most frequently targeted by these lesions 
(and metastases from other cancers as well) are those 
with high blood flow: the vertebrae, the ribs, and the 
hips (58). Its high soft-tissue contrast is very useful for 
exploring the marrow and paraosseous structures (e.g. 
spinal canal) with a detection limit of 2 mm (59). Whole-
body MRI has displayed 100% sensitivity, 80% specific-
ity of 80%, and 96% accuracy in the detection of bone 
metastases in cancer patients, and its performance is only 
slightly inferior in patients harboring more than one 
lesion (sensitivity,  specificity, and accuracy: 94, 76, and 
91% respectively (59). The addition of background body 
signal suppression (DWIBS) significantly increases the 
accuracy of MRI for bone metastasis detection, and the 
accuracy of this approach has proved to be similar to that 
of 18F- fluorodeoxyglucose PET (94%) in a small cohort of 
23 patients (60).
In patients with solid tumors, MRI is superior to CT 
for the detection of brain metastases because it provides 
higher soft-tissue contrast, no bone artifacts, and fewer 
partial volume effects. Paramagnetic contrast agents also 
produce significantly stronger enhancement than those 
used with CT (61). In the presence of multiple brain 
lesions, roughly 20% of the lesions identified with MRI 
are missed on CT (61).
Approximately, 0.5% of DTC metastases are located 
in the liver. They usually develop late in the course of 
the disease in patients with other distant metastases 
(62). Evidence-based guidelines recommend CT or MRI 
identification of liver metastases. Data are lacking in DTC, 
but MRI is considered preferable to CT for exploring liver 
metastases from most endocrine tumors (63, 64).
Functional imaging
Radioiodine imaging
Radioiodine imaging exploits the capacity of thyroid cells 
to take up iodine from the circulation, which is mediated 
by the sodium iodine symporter (NIS). This capacity is 
generally preserved in thyroid cancer cells although they 
might display decreased (65, 66) or even absent (67, 68) 
NIS expression. Iodine metabolism in thyroid cancer 
cells can also be influenced by somatic mutations, such 
as BRAF V600E, which is associated with downregulated 
expression of iodide-metabolizing genes (69). Radioiodine 
can be used to obtain planar or three-dimensional 
images (classic radioiodine scintigraphy vs single-photon 
emission computed tomography, SPECT).
Diagnostic whole-body radioiodine scintigraphy
Although the accuracy of a diagnostic WBS is 
approximately 84–90%, its specificity (91–100%) far 
exceeds its sensitivity (27–55%) (70, 71, 72, 73). It is the 
most sensitive tool for thyroid remnant detection and 
thyroid remnant ablation assessment (74, 75). It is also 
useful for early detection of distant metastases. These 
lesions, however, are relatively uncommon in DTC 
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patients: they are found in only ~3% of DTC patients at 
diagnosis and in 10% or less during follow-up (3, 76, 77). 
The ATA thus recommends routine diagnostic WBS during 
follow-up only when the risk of persistent/recurrent 
disease and extracervical metastases is intermediate or 
high (Fig. 3) (9). Even in these cases, there is no need to 
repeat the DxWBS if the RxWBS yields negative findings, 
especially if Tg production is undetectable and the Tg 
antibody assay is negative (17, 78, 79, 80, 81). In contrast, 
DxWBS can be useful for monitoring (and for planning 
additional imaging work-up) of distant and/or local foci 
of radioiodine uptake revealed on post-therapeutic WBSs, 
and it is also an option for assessing the presence of distant 
metastases when positive Tg antibody levels render serum 
Tg levels unreliable markers of disease (9).
DxWBS can also be helpful in calculating therapeu-
tic doses of radioiodine (82). It is important to recall, 
however, that a diagnostic dose of 131I (the isotope most 
widely used for diagnostic scans in DTC patients) can 
reportedly reduce the uptake of radioiodine subsequently 
administered for therapeutic purposes, particularly when 
the two administrations are separated by more than 
3 days and fewer than 7 days – a phenomenon known as 
the ‘stunning effect’ (83). However, in a recent study of 
two consecutive cohorts of DTC patients undergoing RRA, 
ablation rates and detection rates of disease recurrence 
were similar in the patients whose ablations were or were 
not preceded by a diagnostic scan (84). Stunning is not 
caused by diagnostic scans performed with 123I (85, 86, 
87). This pure gamma emitter is ideal for use with mod-
ern gamma cameras and provides higher image resolution 
than 131I. Its use is limited, however, by its high cost and 
low availability (due to its short half-life).
WBS has a number of practical drawbacks. The detec-
tion limit depends on several factors, including the activity 
administered, the timing of image acquisition following 
RAI administration, the type of equipment used (crystal 
thickness), and the patient’s renal function status (88). A 
successful scan also requires a lengthy period of patient 
preparation (3–4 weeks) to maximize tracer uptake. This 
involves a low iodine diet and elevation of TSH levels by 
withdrawal of thyroid hormone replacement therapy. The 
latter is often associated with unpleasant symptoms of 
hypothyroidism. Administration of recombinant human 
TSH (rhTSH) is an effective alternative that is more expen-
sive but decidedly better tolerated. In addition, patients 
who have recently undergone computed tomography 
scanning with iodinated contrast medium must wait 
4–8 weeks before they have a radioiodine WBS (89). Radia-
tion exposure is also a consideration. The examination 
involves administration of a radioactive tracer (albeit at 
low doses). The radiation risk also involves persons who are 
in contact with the patients, so radioprotection measures 
must be adopted for the 10–15 days following the scan. 
Disease is anatomically located based on the RAI uptake 
observed on the planar whole-body image and, if neces-
sary, images of specific body regions, such as the neck. The 
precision of this approach is nonetheless limited. Because 
RAI can be concentrated by both normal and neoplastic 
thyroid tissue, RAI scintigraphy cannot be used to iden-
tify foci of persistent/recurrent disease in the thyroid bed. 
False-positive results can also be caused by the physiologic 
or pathologic accumulation of radioiodine in nonthyroi-
dal tissues and body fluids (Table 2) (90). The sensitivity 
of WBS can be reduced in the presence of large amounts 
of normal thyroid tissue: these remnants can sequester 
almost all of the administered 131I activity, thereby reduc-
ing visualization of smaller metastatic lesions (9). When 
a large remnant is visualized on post-therapeutic WBS, a 
diagnostic WBS can be evaluated to reassess the presence 
of local or distant metastases (9). WBS is also of no value 
in the patients whose tumors have lost the ability to con-
centrate RAI (91), a phenomenon encountered in up to 
two-thirds of patients with distant metastases (the subpop-
ulation most likely to benefit from WBS) (92).
Single-photon emission computed tomography/
computed tomography
In single-photon emission computed tomography (SPECT), 
the two-dimensional tomographic images acquired with 
the SPECT gamma camera are elaborated to provide a three-
dimensional representation of the region being examined. 
SPECT–CT involves the co-registration and fusion of SPECT 
images and those acquired with a conventional CT scan. 
This dual-modality approach improves the localization 
Table 2 False-positive radioiodine uptake.
Physiologic uptake
 Choroid plexus
 Lachrymal sac and tears
 Nasopharynx and nasal secretions
 Salivary glands and saliva, oral cavity, esophagus
 Breast and breast milk
 Liver, gallbladder, and biliary tract
 Kidneys, urinary tract, and urine
 Stomach
 Large bowel and feces
Pathologic uptake
 Inflammation
 Benign tumors
 Malignant tumors
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and facilitates measurement of lesions seen on SPECT 
scintigraphy. The specificity of SPECT–CT is high (up to 
100%) and the sensitivity is 50% (93).
Costs and availability are major considerations in 
decisions on the use of SPECT–CT. In the follow-up of 
patients with DTC, SPECT–CT is performed with diagnos-
tic or therapeutic activities of radioiodine. Consequently, 
it has the same drawbacks as RAI WBS in terms of patient 
preparation and the need for postscan radioprotection 
measures. On the other hand, the SPECT–CT fusion 
images elaborated by the scanner software allow more 
precise localization of foci of RAI uptake as well as lesions 
that are not RAI-avid. For this reason, SPECT–CT is less 
likely to produce false-positive and indeterminate results 
(94, 95), and it reportedly provides a gain in information 
over that furnished by WBS alone in 35–68% of patients 
(94, 96, 97). In a recent study, SPECT–CT performed after 
RRA revealed additional disease foci (neck lymph nodes 
and/or distant metastases) in about 9% of the patients 
whose RxWBS showed uptake only in the thyroid bed. 
Results of this type were particularly common when stim-
ulated Tg levels were ≥1.8 ng/mL. In patients with RxWBS 
findings suggestive of cervical lymph node metastasis, 
40% of the lesions were reclassified as normal thyroid 
remnants on the basis of SPECT–CT results (98).
18F-fluorodeoxyglucose positron emission 
tomography
Positron emission tomography is being employed more 
and more often for all types of cancers. The most common 
tracer used in clinical settings is 18FDG, a glucose analog that 
is taken up by benign as well as neoplastic cells. The latter 
cells’ demand for glucose, however, is markedly increased 
owing to their reliance on anaerobic glycolysis, which 
is far less efficient for energy production than oxidative 
phosphorylation. The metabolic information provided by 
this technique is the basis for PET’s use as a diagnostic and 
prognostic tool in cancer patients (e.g. for evaluating the 
response to treatment and estimating the risk of death). The 
PET/CT is a more recently developed technique that uses 
integrated scanners to acquire PET and CT images in a single 
session. The combination of functional and morphologic 
data furnished by this approach substantially improves the 
anatomic localization of lesions. Two meta-analyses analyzed 
the diagnostic performances of 18FDG PET and 18FDG 
PET/CT for the detection of persistent/recurrent DTC in 
patients with detectable Tg and no evidence of RAI uptake 
(99, 100). In both cases, the patient-based sensitivity of 
PET/CT was appreciably higher than PET alone (93–94% 
vs 83–84% for 18FDG PET). The ATA strongly recommends 
18FDG PET/CT for high-risk DTC patients with elevated basal 
or stimulated serum Tg (generally >10 ng/mL) and negative 
findings on radioiodine imaging during follow-up (9). In 
case of lower thyroglobulin levels, 18FDG PET/CT can be 
false negative due to the presence of microscopic disease. 
The specificities of 18FDG PET alone and PET/CT methods 
were similar (81–84%) (99, 100). This is due to the fact that 
inflammation also increases FDG uptake. When 18FDG PET 
is used to stage DTC, care must be taken to differentiate 
increased uptake by thyroid-derived neoplastic tissue from 
that observed in nonthyroid tumors (Fig. 4). Uptake can also 
be increased merely by the presence of inflammation (e.g. 
reactive lymph nodes, inflammatory joint changes) (Fig. 4).
Disease relapse and staging
18FDG PET findings lead to changes in patient management 
strategies (generally involving the surgical plan) in about 
30% of the cases (101, 102, 103). As noted, however, false 
positivity related to inflammation is possible. Therefore, 
if surgery is planned on the basis of FDG uptake, the true 
metastatic nature of cervical lymph nodes must always be 
verified intraoperatively or preoperatively via FNA.
18FDG PET positivity in thyroid cancer is influenced 
by several other factors, including primary tumor histol-
ogy, the presence of RAI-refractory disease, overall tumor 
burden, disease localization, and TSH levels at the time 
of the scan. 18FDG avidity is most commonly seen in the 
more aggressive DTC forms. Histopathological analysis 
of distant metastases from 70 18FDG-avid thyroid tumors 
revealed that almost half were poorly differentiated can-
cers, 20% were tall-cell variants, and 9% were Hürthle cell 
carcinomas. However, almost one-fourth (23%) were well-
differentiated cancers. In 16 (37%) of the 43 patients whose 
primary tumor was also analyzed, the 18FDG-avid metasta-
ses presented more aggressive histological features than the 
primaries (104). Distant metastases that take up 18FDG are 
frequently refractory to radioactive iodine therapy, even 
at high doses, and most of these lesions exhibit signs of 
metabolic progression during the first year after treatment 
(105). 18FDG uptake in RAI-refractory thyroid cancer is cor-
related with loss or downregulation of NIS expression and 
increased expression of glucose transporter 1. The BRAF 
V600E mutation can also cause this metabolic pattern, 
and this may explain the 18FDG uptake observed in well-
differentiated thyroid cancer harboring this mutation (69). 
Patients with detectable thyroglobulin production and sus-
pected recurrence are sometimes referred for empirical RAI 
treatment to search and treat disease localization. However, 
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in roughly one-third of these patients, the post-treatment 
whole-body RAI scan is negative and 18FDG PET is more 
sensitive to detect recurrence, suggesting that it might be 
useful to perform 18FDG PET before giving empiric radioac-
tive iodine treatment in these patients (106).
In addition to its recommended role in the follow-up 
of patients with aggressive histology and RAI-refractory 
disease, FDG PET is also potentially useful in the primary 
staging of high-risk patients (Table 1). Lee et al. retrospec-
tively analyzed 258 patients who underwent RRA and 
18FDG PET/CT during the same period of time. Compared 
with the post-treatment WBS, 18FDG PET/CT revealed addi-
tional positive findings in 25% of the patients with high- 
or intermediate-risk thyroid cancers (pT3-T4N1 and tumor 
size >2 cm) but only 3–6% of those with lower-risk tumors 
(T3-T4 N0 or T1-T2 N1 and size <2 cm), and the gain in 
information led to a change in management in 17% of the 
cases (107). Nascimento et al. retrospectively evaluated 38 
patients with aggressive thyroid cancer  histotypes and no 
evidence of disease after surgery. 18FDG PET/CT performed 
after the first RRA revealed persistent disease in 15 (39%) 
of these patients; only 12 of these cases were identified 
with the post-therapeutic RAI WBS (108). Of the 86 lesions 
detected in this cohort, 41% were detected only by 18FDG 
PET/CT and 31% were seen only on the post-therapeutic 
WBS, indicating the two techniques play complementary 
roles (108). Additional studies are nonetheless necessary to 
validate the utility of this approach in routine practice.
The serum thyroglobulin level is an indirect index of 
the tumor burden. Current guidelines recommend 18FDG 
PET/CT when Tg levels exceed 10 ng/mL (9), and this 
threshold has been used in several studies. However, FDG 
PET positivity is also associated with lower thyroglobulin 
levels (101, 109). For this reason, lower thresholds have 
been proposed. Giovanella et al., for example, suggested a 
level of 4.6 ng/mL, which was associated with a sensitivity 
of 96% (110). Based on a subsequent analysis of 102 cases, 
the same investigators also demonstrated that 18FDG-PET 
positivity is predicted by a serum thyroglobulin doubling 
time of less than 1 year, regardless of the Tg level itself (111).
Ultrasonography is still the best tool for detection 
of cervical lymph node metastases, but 18FDG PET can 
be useful for identifying recurrence in areas that are dif-
ficult or impossible to explore sonographically, such as 
the upper mediastinum or the retropharyngeal region 
(101, 112). As for distant metastases, 18FDG PET can often 
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Figure 4
18FDG PET findings in the follow-up of differentiated thyroid cancer. 18FDG PET/CT in a patient with tall-cell variant thyroid cancer 
(panel A) showed a retroclavicular left metastatic lymph node (panel B, axial view) and high and focal uptake also in the left 
clavicle (panel C, axial view) suspicious of bone metastases. MRI confirmed to be arthrosis (panel D). FDG PET in a patient with 
recurrent papillary thyroid cancer (panel E). High FDG uptake was detected in a superior mediastinal lymph node (panel F, axial 
view) and in mesenteric lymph node (panel G, axial view) suspicious for recurrence. Biopsy confirmed thyroid cancer recurrence in 
the mediastinal lymph node, but it was in favor of a B cells lymphoma in the mesenteric lymph node.
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detect small bone lesions that are missed on CT or MRI 
scans. However, CT is still the method of choice for iden-
tifying lung metastasis, especially the micronodular form 
that is so common in thyroid cancer. These lesions are 
often 18FDG-negative due to a partial volume effect (113).
The sensitivity of 18FDG PET can be influenced by TSH 
stimulation. Conflicting results have been reported on this 
issue. However, in a recent meta-analysis of seven prospec-
tive controlled clinical trials (168 patients), per-patient 
and per-lesion analyses both revealed more positive find-
ings and a better tumor/background ratio when 18FDG PET 
was performed under TSH stimulation than when it was 
done during LT4 treatment (114). However, 18FDG PET 
performed after the administration of rhTSH has also been 
associated with false-positive findings, especially in cervi-
cal lymph nodes. As noted above, positive 18FDG findings 
must be interpreted with caution (102). If, for practical rea-
sons, 18FDG PET cannot be performed under TSH stimula-
tion during follow-up, it can be done at the time of RAI 
treatment to take advantage of the TSH stimulation.
Prognostic value
In DTC patients with distant metastases, reported 10-year 
survival rates range from 25 to 42%, and the presence of 
RAI-refractory disease is a major determinant of mortality 
(92). 18FDG uptake is currently considered an important 
tool for predicting overall survival and response to 
therapy in this population. In a study of 80 patients with 
distant metastases from thyroid cancer, 18FDG uptake was 
the only independent predictor of overall survival: rates 
at 2 years were 100% in patients with 18FDG-negative 
lesions but only 60% for those who were 18FDG-positive. 
Furthermore, in the PET-positive subgroup, overall survival 
was unrelated to the lesions’ RAI avidity. Mortality was 
also associated with the 18FDG uptake level (SUV Max 
of >5) and number of 18FDG-avid lesions (>10) (115), 
which is consistent with previous findings (116). Wang 
et al. found no significant response to radioactive iodine 
therapy in lesions that displayed 18FDG uptake, even those 
that also took up radioactive iodine (105). 18FDG uptake 
is also correlated with other clinical factors that predict 
nonsurvival and/or nonresponse to 131I treatment, such as 
age over 45 years and the presence of necrosis (115, 116).
Other radiopharmaceuticals
PET can also be performed with iodine-124 (124I). The 
sensitivity of this approach exceeds that of diagnostic 
and therapeutic WBS done with 131I not only because 
it provides tomographic images, but 124I PET also offers 
higher resolution (117, 118, 119). Nonetheless, it has also 
been associated with false-negative findings in patients 
with miliary lung nodules (120). The half-life of 124I 
(4.2 days) allows the acquisition of sequential images for 
uptake quantification over time. 124I PET-guided lesional 
3D dosimetry together with blood clearance studies can 
predict the absorbed lesion dose, improve selection of the 
safest and most effective 131I activity to administer, and 
predict responses to RAI treatment (121, 122). Nowadays, 
124I PET is used almost exclusively in research settings 
owing to the limited availability of the tracer and the 
growing use of SPECT–CT for post-therapeutic 131I scan. 
18F-Fluoride PET has been proposed for evaluating bone 
metastases from thyroid cancer, but the lytic nature of 
these lesions makes their evaluation difficult (123).
The performance of a new hybrid PET/MRI machine 
has recently been evaluated in thyroid cancer. Vrachimis 
et al. compared FDG PET/MRI with FDG PET/CT in DTC 
patients with detectable thyroglobulin production and 
found that the new method offered no diagnostic gains: 
recurrence detection rates were actually lower with FDG 
PET/MRI (85% vs 97% for FDG PET/CT) (124). Iodine 
124 PET/MRI has also been used for lesion detection 
and dosimetry in high-risk thyroid cancer patients with 
lymph nodes metastases. The authors reported that MRI 
was superior to CT for identifying pathological lymph 
nodes, especially those smaller than 10 mm (125), but this 
issue requires further study.
Conclusions
The diagnostic imaging studies reviewed above play 
fundamental roles in post-treatment surveillance of 
patients with DTC. As in other settings, the key to success 
is selecting the proper tool(s) for the task at hand.
Figure 3 summarizes the current recommendations of 
the ATA for rational use of imaging studies during DTC 
follow-up assessments, including post-treatment stag-
ing and subsequent surveillance. The choice of first-line 
tools for this process may vary somewhat from center to 
center, depending on local resources. Cost and availabil-
ity have to be considered. Studies available only in a few 
highly specialized centers may be useful in many patients, 
and depending on local resources, they may have a place 
in the first-line armamentarium (e.g. in a facility that 
includes a nuclear medicine department, WBS/SPECT–CT 
can be useful for routine use in several patient subsets). 
www.eje-online.org
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However, they are likely to be problematic for repeated 
use on patients being followed in facilities not located in 
metropolitan areas. Likewise, safety and tolerability are 
always valid concerns, but they play particularly impor-
tant roles in ensuring patients’ continuing participation 
in routine surveillance activities.
In the end, however, the final choice will be deter-
mined largely by the likelihood and probable location of 
persistent/recurrent disease and the sensitivity of the test 
for detecting this type of disease. In this context, the fact 
that over 85% of all thyroid cancers are PTCs (126, 127) 
is highly pertinent since these tumors spread via the lym-
phatics. One out of four PTC patients will develop cervical 
lymph node metastases (http://seer.cancer.gov/stat-facts/
html/thyro.html; last accessed 17 January 2016), whereas 
distant metastases are rare in PTC, particularly in the 
absence of cervical lymphadenopathy. Given its high sen-
sitivity for thyroid bed and cervical lymph node lesions, its 
excellent safety and tolerability profiles, wide availability, 
and low cost, neck US is thus an ideal first-line imaging tool 
for use in almost all DTC patients and in almost all settings.
Second-line imaging studies are used more selectively 
and in cases where there is at least some reason to suspect 
metastasis (elevated or increasing levels of serum Tg, rising 
Tg antibody titers, atypical first-line imaging findings). 
The importance of specificity increases at the second-line 
level, and the higher risk status also justifies the use of 
methods that are most costly, less accessible, and/or more 
likely to be associated with some adverse effects.
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